Publications by authors named "Richard Markus"

Claim this Profile
V
Velocity encoded mitral valve inflow cine: A novel and more reproducible method to determine cardiac rest periods during coronary magnetic resonance angiography.
Richard Markus, Animesh Tandon, Munes Fares, Jeanne Dillenbeck, Gerald F Greil

JRSM Cardiovasc Dis· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interchangeability Of Biological Drug Products-FDA Draft Guidance.
Laszlo Endrenyi, Richard Markus

J Biopharm Stat· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Review of the Totality of Evidence Supporting the Development of the First Adalimumab Biosimilar ABP 501.
Richard Markus, Helen J McBride, Monica Ramchandani, Vincent Chow, Jennifer Liu

Adv Ther· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, single-blind, single-dose study to assess the pharmacokinetic equivalence of the biosimilar ABP 215 and bevacizumab in healthy Japanese male subjects.
Vladimir Hanes, Vincent Chow, Zhiying Pan, Richard Markus

Cancer Chemother Pharmacol· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: A phase I, randomized, single-dose study evaluating the pharmacokinetic equivalence of biosimilar ABP 215 and bevacizumab in healthy adult men.
Richard Markus, Vincent Chow, Zhiying Pan, Vladimir Hanes

Cancer Chemother Pharmacol· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I, randomized, single-dose study evaluating the pharmacokinetic equivalence of biosimilar ABP 215 and bevacizumab in healthy adult men.
Richard Markus, Vincent Chow, Zhiying Pan, Vladimir Hanes

Cancer Chemother Pharmacol· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality Improvement Initiative to Increase the Use of Nasogastric Hydration in Infants With Bronchiolitis.
Mythili Srinivasan, Cassandra Pruitt, Erin Casey, Keerat Dhaliwal, Cori DeSanto, Richard Markus

Hosp Pediatr· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Developing the Totality of Evidence for Biosimilars: Regulatory Considerations and Building Confidence for the Healthcare Community.
Richard Markus, Jennifer Liu, Monica Ramchandani, Diana Landa, Teresa Born

BioDrugs· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, single-blind, single-dose study evaluating the pharmacokinetic equivalence of proposed biosimilar ABP 980 and trastuzumab in healthy male subjects.
Vladimir Hanes, Vincent Chow, Nan Zhang, Richard Markus

Cancer Chemother Pharmacol· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomised, single-blind, single-dose, three-arm, parallel-group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumab.
Primal Kaur, Vincent Chow, Nan Zhang, Michael Moxness, Arunan Kaliyaperumal, Richard Markus

Ann Rheum Dis· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The use of pharmacometrics to optimize biosimilar development.
Mike Dodds, Vincent Chow, Richard Markus, Juan José Pérez-Ruixo, Danny Shen

J Pharm Sci· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Estimation of Cachexia among Cancer Patients Based on Four Definitions.
Kathleen M Fox, John M Brooks, Shravanthi R Gandra, Richard Markus, Chiun-Fang Chiou

J Oncol· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial.
Karim Fizazi, Linda Bosserman, Guozhi Gao, Tomas Skacel, Richard Markus

J Urol· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives.
Andrew D Zelenetz, Islah Ahmed, Edward Louis Braud, James D Cross, Nancy Davenport-Ennis, Richard Markus

J Natl Compr Canc Netw· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recent time trends in the epidemiology of stage IV prostate cancer in the United States: analysis of data from the Surveillance, Epidemiology, and End Results Program.
Karynsa Cetin, Jennifer L Beebe-Dimmer, Jon P Fryzek, Richard Markus, Michael A Carducci

Urology· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial.
Karim Fizazi, Linda Bosserman, Guozhi Gao, Tomas Skacel, Richard Markus

J Urol· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial.
Gabriela Senti, Bettina M Prinz Vavricka, Iris Erdmann, Mella I Diaz, Richard Markus

Proc Natl Acad Sci U S A· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting the receptor activator of nuclear factor-kappaB (RANK) ligand in prostate cancer bone metastases.
Fred Saad, Richard Markus, Carsten Goessl

BJU Int· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis.
Ronald L Gibson, George Z Retsch-Bogart, Christopher Oermann, Carlos Milla, Joseph Pilewski, Richard Markus

Pediatr Pulmonol· July 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis